Trial Profile

A phase II clinical trial assessing iNexin™

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 11 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACT 1 (Primary)
Indications Dry eyes
Focus Therapeutic Use
Sponsors Xequel Bio

Most Recent Events

08 May 2023 According to a Xequel Bio media release, Societal CDMO, Inc announced that it has been selected by Xequel Bio, Inc.to provide CDMO services to support the ongoing clinical development of a patented new chemical entity based on its aCT1 platform. The agreement spans a range of Societal CDMO's offerings including culminating in cGMP manufacturing of the compound and placebo for this trial.
19 Jul 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com